Insights Into Intestinal Flora in Metabolic Dysfunction-Associated Steatotic Liver Disease

Area of Science:

• Hepatology
• Microbiology
• Metabolic Diseases

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD), including nonalcoholic fatty liver (NAFL) and metabolic dysfunction-associated steatohepatitis (MASH), is a growing global health concern.
• MASLD leads to severe liver damage, including fibrosis, cirrhosis, and cancer.
• Emerging research highlights the critical role of the gut microbiome in MASLD development and progression.

Purpose of the Study:

• To explore the intricate relationship between intestinal flora and MASLD.
• To underscore the therapeutic potential of targeting the gut microbiota for MASLD treatment.

Main Methods:

• Review of current scientific literature on gut microbiota and MASLD.
• Analysis of mechanisms linking gut dysbiosis to liver injury.
• Identification of potential therapeutic targets within the intestinal flora.

Main Results:

• Gut dysbiosis exacerbates MASLD by impairing the intestinal barrier, leading to bacterial translocation and hepatic injury.
• Intestinal flora contributes to NAFLD pathogenesis via endotoxin production and altered bile acid metabolism.
• Gut microbiota-derived metabolites are increasingly recognized for their regulatory role in MASLD.

Conclusions:

• The gut microbiome is a key factor in MASLD development.
• Modulating intestinal flora presents a promising avenue for novel pharmacological interventions against MASLD.
• Further research into gut flora-related metabolites could unlock new treatment strategies.